A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With Bevacizumab or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study Evaluating the Efficacy and Safety of Onartuzumab (MetMAb) in Combination With Bevacizumab or Onartuzumab Monotherapy in Patients With Recurrent Glioblastoma

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2017

At a glance

  • Drugs Onartuzumab (Primary) ; Bevacizumab
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 05 Dec 2016 Primary endpoint (Progression-free survival (investigator-assessed): onartuzumab + bevacizumab versus placebo + bevacizumab) has not been met according to the results published in the Journal of Clinical Oncology.
    • 05 Dec 2016 Results published in the Journal of Clinical Oncology.
    • 24 Oct 2015 Status changed from active, no longer recruiting to completed as per European Clinical Trials Database record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top